Actively Recruiting
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Led by Bruce Robinson, MD · Updated on 2025-09-17
100
Participants Needed
1
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
CONDITIONS
Official Title
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy-confirmed squamous cell carcinoma and/or basal cell carcinoma
- Skin cancer not previously treated by other methods
You will not qualify if you...
- Pregnant at the time of treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bruce Robinson, MD
New York, New York, United States, 10022
Actively Recruiting
Research Team
G
Gillian Nanni, Research Coordinator, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here